查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1667937

克拉维酸系列 API 市场 - 全球产业规模、份额、趋势、机会和预测，按类型、应用、地区和竞争细分，2020-2030 年预测

Clavulanic Acid Series API Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球克拉维酸系列 API 市值为 3.9421 亿美元，预计到 2030 年将达到 5.887 亿美元，预测期内复合年增长率为 6.87%。全球克拉维酸系列 API 市场主要受组合抗生素需求不断增长的推动。克拉维酸透过抑制细菌产生的抵抗抗生素的β-内酰胺酶来增强青霉素类抗生素的有效性。细菌抗药性的增加和对广谱抗生素的需求不断增长是推动市场成长的重要因素。新兴市场医疗保健覆盖率的扩大以及肺炎、泌尿道感染和呼吸道感染等感染的日益流行进一步增加了对克拉维酸类药物的需求。对新药配方的持续研究以及人类和兽医学中復方药物的日益使用预计将维持市场的成长。

市场概况
预测期 2026-2030
2024 年市场规模 3.9421亿美元
2030 年市场规模 5.887亿美元
2025-2030 年复合年增长率 6.87%
成长最快的领域 阿莫西林和克拉维酸钾
最大的市场 亚太地区

主要市场驱动因素

抗生素抗药性不断上升，需要有效的治疗

主要市场挑战

生产成本上升和供应链中断

主要市场趋势

兽医业需求增加

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球克拉维酸系列原料药市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按类型（克拉维酸钾、阿莫西林和克拉维酸钾、克拉维酸钾与微晶纤维素、克拉维酸钾与二氧化硅）
    • 依用途（口服药物和注射药物）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美克拉维酸系列原料药市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 加拿大
    • 墨西哥

第七章：欧洲克拉维酸系列原料药市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太克拉维酸系列原料药市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：南美洲克拉维酸系列原料药市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲克拉维酸系列原料药市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 产品发布（如果有）
  • 最新动态

第 13 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 14 章：竞争格局

  • Apotex Inc.
  • Centrient Holding BV
  • CKD BiO Corp.
  • Fidia Farmaceutici SpA
  • GlaxoSmithKline Plc
  • Hikma Pharmaceuticals Plc
  • Sandoz Group AG
  • Novopharm Formulations Private Limited
  • Rochem International Inc.
  • Senova Technology Co. Ltd.

第 15 章：策略建议

第16章 调査会社について・免责事项

简介目录
Product Code: 27678

Global Clavulanic Acid Series API Market was valued at USD 394.21 Million in 2024 and is expected to reach USD 588.70 Million by 2030 with a CAGR of 6.87% during the forecast period. The global clavulanic acid series API market is primarily driven by the increasing demand for combination antibiotics. Clavulanic acid is used to enhance the effectiveness of penicillin-based antibiotics by inhibiting beta-lactamase enzymes that bacteria produce to resist antibiotics. The rise in bacterial resistance and the growing need for broad-spectrum antibiotics are significant factors fueling market growth. The expansion of healthcare access in emerging markets and the increasing prevalence of infections such as pneumonia, urinary tract infections, and respiratory infections further contribute to the demand for clavulanic acid-based medicines. The ongoing research into new drug formulations and the increasing use of combination drugs in both human and veterinary medicine are expected to sustain the market's growth.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 394.21 Million
Market Size 2030USD 588.70 Million
CAGR 2025-20306.87%
Fastest Growing SegmentAmoxicillin & Potassium Clavulanate
Largest MarketAsia Pacific

Key Market Drivers

Rising Antibiotic Resistance and Need for Effective Treatments

Antibiotic resistance remains one of the most pressing challenges facing global healthcare today. Bacteria have evolved numerous mechanisms to resist antibiotics, rendering many traditional treatments ineffective. This growing problem is particularly severe in healthcare settings, where infections like pneumonia, bloodstream infections, and urinary tract infections are becoming harder to treat due to resistant strains. The rise of multi-drug-resistant (MDR) and extensively drug-resistant (XDR) bacteria highlights the urgent need for effective solutions. Clavulanic acid, when combined with beta-lactam antibiotics such as amoxicillin, becomes an essential tool in the fight against these resistant pathogens. In January 2021, the central government revealed the names of the first three companies eligible for financial support under the production-linked incentive (PLI) scheme aimed at promoting domestic manufacturing of critical key starting materials (KSMs), drug intermediates, and active pharmaceutical ingredients (APIs). The companies include Aurobindo Pharma, based in Hyderabad, Kinvan Pvt Ltd from Mumbai, and the public sector firm Karnataka Antibiotics and Pharmaceuticals.

Key Market Challenges

Rising Production Costs and Supply Chain Disruptions

The production of clavulanic acid is a complex process that requires specialized fermentation and synthesis techniques. The production of high-quality clavulanic acid APIs involves significant raw material costs and capital investment in specialized equipment. Manufacturers often face fluctuating prices for key raw materials such as fermentation substrates and chemicals, which can result in increased production costs. These cost pressures can affect the final pricing of clavulanic acid-based antibiotics, especially in price-sensitive markets where affordability is a key concern.

The global supply chain for pharmaceutical ingredients can be subject to disruptions, whether from natural disasters, geopolitical factors, or trade restrictions. The COVID-19 pandemic, for example, highlighted the vulnerabilities in the global pharmaceutical supply chain, as manufacturers faced difficulties sourcing raw materials, facing shipping delays, and experiencing interruptions in production. Such disruptions can lead to delays in API supply, reduced availability of key products, and higher production costs, which could impede the growth of the clavulanic acid market.

Key Market Trends

Increased Demand from the Veterinary Sector

An emerging driver for the Global Clavulanic Acid Series API Market is the increasing demand for clavulanic acid-based antibiotics in the veterinary sector. Animals, especially livestock such as poultry, cattle, and pigs, are often treated with antibiotics to prevent infections and promote growth. The rise in animal infections caused by bacterial pathogens resistant to conventional antibiotics has spurred the demand for combination therapies that include clavulanic acid. These antibiotics are effective in treating a wide variety of bacterial infections in animals, including respiratory and gastrointestinal infections.

The growing global demand for animal protein, especially in emerging markets, has led to an increase in livestock farming. Consequently, veterinary antibiotics that combine clavulanic acid are becoming more widely used to control bacterial infections in animals. The increasing regulations and focus on animal welfare also ensure that only effective antibiotics, such as those containing clavulanic acid, are used in livestock, driving demand in the veterinary market and thus contributing to the overall growth of the clavulanic acid API market.

Key Market Players

  • Apotex Inc.
  • Centrient Holding B.V.
  • CKD BiO Corp.
  • Fidia Farmaceutici S.p.A.
  • GlaxoSmithKline Plc
  • Hikma Pharmaceuticals Plc
  • Sandoz Group AG
  • Novopharm Formulations Private Limited
  • Rochem International Inc.
  • Senova Technology Co. Ltd.

Report Scope:

In this report, the Global Clavulanic Acid Series API Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clavulanic Acid Series API Market, By Type:

  • Potassium Clavulanate
  • Amoxicillin & Potassium Clavulanate
  • Potassium Clavulanate with Avicel
  • Potassium Clavulanate with Silicon Dioxide

Clavulanic Acid Series API Market, By Application:

  • Oral Medications
  • Injectable Medications

Clavulanic Acid Series API Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clavulanic Acid Series API Market.

Available Customizations:

Global Clavulanic Acid Series API market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clavulanic Acid Series API Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Potassium Clavulanate, Amoxicillin & Potassium Clavulanate, Potassium Clavulanate with Avicel, Potassium Clavulanate with Silicon Dioxide)
    • 5.2.2. By Application (Oral Medications and Injectable Medications)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Clavulanic Acid Series API Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Clavulanic Acid Series API Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Clavulanic Acid Series API Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Clavulanic Acid Series API Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Clavulanic Acid Series API Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Clavulanic Acid Series API Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. United Kingdom Clavulanic Acid Series API Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. Italy Clavulanic Acid Series API Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. France Clavulanic Acid Series API Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Clavulanic Acid Series API Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia-Pacific Clavulanic Acid Series API Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Clavulanic Acid Series API Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Clavulanic Acid Series API Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Clavulanic Acid Series API Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Clavulanic Acid Series API Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Clavulanic Acid Series API Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. South America Clavulanic Acid Series API Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Clavulanic Acid Series API Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Clavulanic Acid Series API Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Clavulanic Acid Series API Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. Middle East and Africa Clavulanic Acid Series API Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Clavulanic Acid Series API Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Clavulanic Acid Series API Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Clavulanic Acid Series API Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Apotex Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Centrient Holding B.V.
  • 14.3. CKD BiO Corp.
  • 14.4. Fidia Farmaceutici S.p.A.
  • 14.5. GlaxoSmithKline Plc
  • 14.6. Hikma Pharmaceuticals Plc
  • 14.7. Sandoz Group AG
  • 14.8. Novopharm Formulations Private Limited
  • 14.9. Rochem International Inc.
  • 14.10. Senova Technology Co. Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer